ABT:NYE-Abbott Laboratories (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 114.88

Change

-3.25 (-2.75)%

Market Cap

USD 199.88B

Volume

5.99M

Analyst Target

USD 115.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Address: 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
MDT Medtronic PLC

-0.50 (-0.56%)

USD 115.58B
STE STERIS plc

-3.30 (-1.37%)

USD 24.14B
ZBH Zimmer Biomet Holdings Inc

+0.04 (+0.04%)

USD 21.64B
SNN Smith & Nephew SNATS Inc

-0.25 (-0.81%)

USD 13.74B
BIO Bio-Rad Laboratories Inc

+6.79 (+2.04%)

USD 9.45B
GMED Globus Medical

+0.25 (+0.36%)

USD 9.39B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.26B
PEN Penumbra Inc

+8.52 (+4.55%)

USD 7.77B
GKOS Glaukos Corp

+0.73 (+0.60%)

USD 6.94B
INSP Inspire Medical Systems Inc

+1.69 (+0.82%)

USD 6.08B

ETFs Containing ABT

UMDV:SW iShares US Medical Device.. 16.05 % 0.00 %

N/A

N/A
EDOC:AU BetaShares Digital Health.. 8.96 % 0.00 %

+0.03 (+-0.44%)

N/A
HART IQ Healthy Hearts ETF 5.30 % 0.00 %

+0.05 (+-0.44%)

USD 9.14M
LIFE:CA Evolve Global Healthcare .. 5.07 % 0.69 %

-0.01 (-0.44%)

CAD 0.22B
LIFE-U:CA Evolve Global Healthcare .. 5.05 % 0.00 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 4.99 % 0.00 %

+0.01 (+-0.44%)

N/A
HHL-B:CA Harvest Healthcare Leader.. 4.99 % 0.00 %

+0.02 (+-0.44%)

N/A
XSSX:LSE Xtrackers - Euro Stoxx 50.. 4.96 % 0.00 %

+1.25 (+-0.44%)

USD 0.05B
DXSP:XETRA Xtrackers - Euro Stoxx 50.. 4.96 % 0.00 %

+0.04 (+-0.44%)

USD 0.05B
FHI:CA CI Health Care Giants Cov.. 4.94 % 0.75 %

-0.09 (-0.44%)

CAD 0.07B
FHI-B:CA CI Health Care Giants Cov.. 4.94 % 0.00 %

N/A

CAD 0.05B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.68 % 0.00 %

-0.22 (-0.44%)

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.50 % 0.00 %

-0.26 (-0.44%)

USD 0.15B
XGES:LSE Xtrackers MSCI Genomic He.. 4.35 % 0.00 %

-0.26 (-0.44%)

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 3.54 % 0.00 %

-0.07 (-0.44%)

USD 2.54B
QDVG:XETRA iShares S&P 500 Health Ca.. 3.53 % 0.00 %

-0.06 (-0.44%)

USD 2.05B
WELG:XETRA Amundi S&P Global Health .. 3.46 % 0.00 %

-0.07 (-0.44%)

N/A
WELS:XETRA Amundi S&P Global Health .. 3.46 % 0.00 %

-0.07 (-0.44%)

N/A
IUAE:CA Invesco S&P US Dividend A.. 3.45 % 0.00 %

N/A

CAD 1.18M
QLTY The 2023 ETF Series Trust.. 3.42 % 0.00 %

-0.14 (-0.44%)

USD 0.44B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 3.41 % 0.00 %

-0.23 (-0.44%)

USD 0.40B
SXLV:SW SPDR S&P U.S. Health Care.. 3.41 % 0.00 %

-0.29 (-0.44%)

N/A
XSHC:LSE Xtrackers MSCI USA Health.. 3.39 % 0.00 %

-41.00 (-0.44%)

USD 0.68B
XUHC:LSE Xtrackers MSCI USA Health.. 3.39 % 0.00 %

-0.60 (-0.44%)

USD 0.64B
IUHC:SW iShares S&P 500 Health Ca.. 3.36 % 0.00 %

-0.08 (-0.44%)

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.36 % 0.00 %

-0.32 (-0.44%)

N/A
ZPDH:F SPDR S&P U.S. Health Care.. 3.34 % 0.00 %

+0.07 (+-0.44%)

USD 0.40B
XUHC:XETRA Xtrackers MSCI USA Health.. 3.28 % 0.00 %

-0.17 (-0.44%)

USD 0.85B
XUHC:SW Xtrackers MSCI USA Health.. 3.28 % 0.00 %

N/A

USD 0.69B
XUHC:F Xtrackers (IE) Public Lim.. 3.22 % 0.00 %

+0.12 (+-0.44%)

USD 0.85B
FHLC Fidelity® MSCI Health Ca.. 3.11 % 0.08 %

-0.02 (-0.44%)

USD 3.02B
AIVL WisdomTree Trust - Wisdom.. 3.01 % 0.00 %

-0.26 (-0.44%)

USD 0.39B
HEAL:CA 2.82 % 0.00 %

N/A

N/A
CURE Direxion Daily Healthcare.. 2.32 % 1.06 %

-0.90 (-0.44%)

USD 0.20B
ANEW ProShares MSCI Transforma.. 2.21 % 0.00 %

-0.10 (-0.44%)

USD 8.76M
HYLG Global X Funds - Global X.. 1.58 % 0.00 %

+0.01 (+-0.44%)

N/A
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

-0.16 (-0.44%)

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+0.11 (+-0.44%)

N/A
PWV Invesco Dynamic Large Cap.. 0.00 % 0.55 %

-0.08 (-0.44%)

USD 0.96B
QDYN 0.00 % 0.37 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

+0.30 (+-0.44%)

USD 5.66B
RWDC 0.00 % 0.00 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

-0.03 (-0.44%)

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.03 (-0.44%)

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

-0.18 (-0.44%)

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

-0.53 (-0.44%)

N/A
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

-0.15 (-0.44%)

CAD 0.65B
XLV Health Care Select Sector.. 0.00 % 0.13 %

-0.26 (-0.44%)

USD 42.19B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

-8.50 (-0.44%)

N/A
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

-0.24 (-0.44%)

N/A
XGDD:LSE Xtrackers - Stoxx Global .. 0.00 % 0.00 %

-0.07 (-0.44%)

N/A
XGSD:LSE Xtrackers Stoxx Global Se.. 0.00 % 0.00 %

-12.00 (-0.44%)

N/A
DXSB:F Xtrackers - Stoxx Global .. 0.00 % 0.00 %

N/A

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

-0.12 (-0.44%)

N/A
DXSB:XETRA Xtrackers - Stoxx Global .. 0.00 % 0.00 %

-0.06 (-0.44%)

USD 0.68B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
IXJ:AU iShares Global Healthcare.. 0.00 % 0.00 %

-1.96 (-0.44%)

USD 1.47B
FUD-A:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.37% 53% F 42% F
Dividend Return 1.50% 78% C+ 35% F
Total Return 5.87% 56% F 37% F
Trailing 12 Months  
Capital Gain 14.56% 62% D 56% F
Dividend Return 2.15% 78% C+ 34% F
Total Return 16.71% 62% D 52% F
Trailing 5 Years  
Capital Gain 37.45% 70% C- 66% D+
Dividend Return 10.92% 90% A- 39% F
Total Return 48.37% 70% C- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.81% 52% F 59% D-
Dividend Return 7.52% 58% F 56% F
Total Return 1.71% 75% C 39% F
Risk Return Profile  
Volatility (Standard Deviation) 19.27% 91% A- 53% F
Risk Adjusted Return 39.01% 79% B- 57% F
Market Capitalization 199.88B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector